Pharma Focus Asia

Genesis Therapeutics Enters AI-driven, Multi-Target Drug Discovery Partnership with Genentech

Tuesday, October 20, 2020

Genesis Therapeutics, a privately-held company inventing and deploying state-of-the-art artificial intelligence (AI) techniques to augment drug discovery and development, today announced that it has entered into a multi-target collaboration agreement with Genentech, a member of the Roche Group. The collaboration leverages Genesis’ graph machine learning and drug discovery expertise to identify innovative drug candidates for therapeutic targets in multiple disease areas. Genesis will receive an upfront payment and is eligible to receive pre-clinical, clinical and regulatory milestone payments, as well as future royalties on Genentech’s sales of approved drugs resulting from the collaboration.

“This partnership with Genentech enables us to leverage our AI technology platform with Genentech’s unmatched capabilities in molecular innovation and structural biology. We look forward to executing rapidly on this opportunity, which has the potential to change the standard of treatment for patients,” said Evan Feinberg, Ph.D., Genesis co-founder and CEO.

Genesis originated from breakthrough AI research at Stanford University’s Pande Lab, where Dr. Feinberg co-invented PotentialNet, a graph convolutional neural network algorithm that represented a leap forward in molecular property prediction when first published in the peer-reviewed journal, ACS Central Science. Since its founding, Genesis has further accelerated its innovation in AI and developed next generation algorithms, thus pioneering the intersection of protein motion -- a key element of drug binding -- with neural networks to develop fast and accurate technology for predicting the potency, selectivity, and ADME properties of drug-like molecules.

James Sabry, M.D., Ph.D., Global Head of Roche Pharma Partnering, stated, “AI can help unlock the next generation of innovative therapies for patients in need of additional options. We are excited to work with Genesis’ team to discover medicines currently out of reach using conventional methods.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024